search
Laverock Therapeutics
Trends
- 1Laverock Therapeutics unveils in vivo programmes in oncology and genetic medicine▼Laverock Therapeutics announces in vivo programmes in oncology and genetic medicine
UK-based gene therapy company Laverock Therapeutics has announced new in vivo programmes focused on oncology and genetic medicine, expanding its pipeline of RNA-based therapies designed to be delivered directly into patients. The company says the move broadens its therapeutic reach beyond earlier ex vivo work, though further details on targets and timelines were not immediately provided.
- 2Laverock Therapeutics unveils in vivo oncology and genetic medicine programs▼Laverock Therapeutics announces in vivo programs in oncology and genetic medicine
Laverock Therapeutics has announced new in vivo programs spanning oncology and genetic medicine, marking an expansion of the company's pipeline into therapies delivered directly within the body. The biotech says the move broadens its development focus in cell and gene therapy. Details on specific targets and timelines have not yet been widely reported.